Fulvestrant Sandoz

Estrogen receptor +ve, locally advanced or metastatic breast cancer in postmenopausal women not previously treated w/ endocrine therapy, or w/ disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on anti-estrogen therapy. In combination w/ palbociclib or abemaciclib for hormone receptor (HR) +ve, human epidermal growth factor receptor 2 (HER2) -ve locally advanced or metastatic breast cancer in women w/ disease progression following endocrine therapy. In combination w/ ribociclib for HR +ve, HER2 -ve locally advanced or metastatic breast cancer in postmenopausal women as initial endocrine-based therapy or following disease progression on endocrine therapy.

IM Adult including elderly 500 mg at intervals of 1 mth, w/ an additional 500 mg dose given 2 wk after the initial dose. Administer as 2 consecutive 5 mL slow inj (1-2 min/inj), 1 in each gluteal area.

Hypersensitivity. Severe hepatic impairment. Pregnancy & lactation.

Cancer Hormone Therapy

L02BA03 - fulvestrant ; Belongs to the class of anti-estrogens. Used in treatment of neoplastic diseases.

POM